Which adverse reactions were most frequently reported as possibly or probably related to Juluca in its Phase III trials?

With limited clinical safety data for Juluca, diarrhoea (2%) and headache (2%) were the most frequently reported adverse reactions considered possibly or probably related to dolutegravir plus rilpivirine in 513 HIV-1-infected subjects in Phase III trials.